<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512457850</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512457850</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epstein–Barr virus neuraxis infection as a trigger for central nervous system demyelinating processes: a case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liguori</surname><given-names>Claudio</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512457850">1</xref>
<xref ref-type="aff" rid="aff2-1352458512457850">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sancesario</surname><given-names>Giuseppe</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512457850">2</xref>
<xref ref-type="aff" rid="aff3-1352458512457850">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Albanese</surname><given-names>Maria</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512457850">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stefani</surname><given-names>Alessandro</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512457850">2</xref>
<xref ref-type="aff" rid="aff3-1352458512457850">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Marciani</surname><given-names>Maria Grazia</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512457850">2</xref>
<xref ref-type="aff" rid="aff3-1352458512457850">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pierantozzi</surname><given-names>Mariangela</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512457850">2</xref>
<xref ref-type="aff" rid="aff3-1352458512457850">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512457850"><label>1</label>Neurophysiopathology Department, University of Rome ‘Tor Vergata’, Italy</aff>
<aff id="aff2-1352458512457850"><label>2</label>Neurology Department, University of Rome ‘Tor Vergata’, Italy</aff>
<aff id="aff3-1352458512457850"><label>3</label>IRCCS Santa Lucia Foundation, Rome, Italy</aff>
<author-notes>
<corresp id="corresp1-1352458512457850">Claudio Liguori, Department of Neurophysiopathology, University of Rome ‘Tor Vergata’, Viale Oxford 81, 00133, Rome, Italy Email: <email>dott.claudioliguori@yahoo.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>380</fpage>
<lpage>381</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Dear Sirs,</p>
<p>Although the origin of MS remains elusive, several studies have focused on different genetic-environmental factors; in particular, the role of Epstein–Barr Virus (EBV) infection and virus-triggered immunopathology have been investigated.<sup><xref ref-type="bibr" rid="bibr1-1352458512457850">1</xref>–<xref ref-type="bibr" rid="bibr2-1352458512457850">2</xref></sup></p>
<p>We report on a 64-year-old male presenting with fever, lethargy, stiff neck, left-trigeminal and right-facial nerves deficit, astasia, sensory loss in lower limbs, hypotonic and areflexic paraparesis. CSF analysis showed lymphocytic and mononuclear pleocytosis, amplifiable EBV-DNA and EBV IgM and IgG. Brain MRI was unremarkable; spinal MRI showed a diffuse T2-weighted high-signal intensity (T2HSI) along the thoracic cord with gadolinium enhancement, and lumbosacral impingement of nerve roots and meninges. The patient achieved a full recovery after intravenous (i.v.) therapy with acyclovir 10 mg/kg t.i.d. and methylprednisolone 1000 mg/day. Combined clinical, CSF and MRI findings led to the diagnosis of encephalomyelomeningoradiculitis related to EBV infection.</p>
<p>After a long period of total well-being, the patient presented two acute episodes of lower limbs sensory-motor deficit and severe sphinteric retention. The episodes were separated by a considerable time and each was followed by almost complete recovery. Neurological examination showed in both episodes brisk tendon reflexes in the lower limbs, bilateral Babinski sign and clonus in Achilles tendon reflexes. On both occasions normal cell count and mild increment of protein, lactate and IgG were detected in the CSF, but intrathecal synthesis of oligoclonal bands (OCBs) was unexpectedly evident at the immunoelectrofocusing. Virology from CSF and serum, as vasculitic and rheumatological screens, was negative. Brain and spinal MRI documented the progressive increment in size and number of T2HSI lesions, not evident previously. Somatosensory and visual evoked potentials (SEPs; VEPs) showed bilateral delay of the P40, N20 and P100 waves. In both episodes, a five-day treatment with i.v. methylprednisolone 1000 mg/day produced a full recovery, except for a residual numbness in the feet and sphinteric retention.</p>
<p>Therefore, episodes were notably associated to: i) neuraxis-MRI documenting the progressive dissemination in time and space of the white matter lesions; ii) CSF intrathecal synthesis of OCBs; iii) altered evoked potentials; iv) response to i.v. corticosteroids.</p>
<p>On this evidence the diagnosis of a demyelinating process occurring after an EBV neuraxis infection was postulated.</p>
<p>MS aetiology is still unknown, but one of the most interesting conjectures is that MS may be primed and perpetuated by a neurotropic agent, possibly a virus, in genetically susceptible subjects, suggesting that a virus may initiate or trigger immunopathological demyelinating processes.<sup><xref ref-type="bibr" rid="bibr1-1352458512457850">1</xref></sup> Different neurotropic viruses have been variously invoked as the possible cause of MS and EBV is considered the outstanding candidate.<sup><xref ref-type="bibr" rid="bibr2-1352458512457850">2</xref></sup> In fact, there is ample documentation that a history of symptomatic primary EBV infection increases the risk of developing MS; moreover, it has been recently hypothesized that EBV can promote inflammatory processes by activating innate immune responses, for example IFNα production,<sup><xref ref-type="bibr" rid="bibr3-1352458512457850">3</xref></sup> although these data are still debated.<sup><xref ref-type="bibr" rid="bibr4-1352458512457850">4</xref></sup></p>
<p>The present case documents a clear relationship between an EBV-CNS infection and the subsequent development of a CNS demyelinating process, probably due to an immunological cross-reaction, showing clinical and paraclinical features in agreement with the McDonald criteria for MS diagnosis.<sup><xref ref-type="bibr" rid="bibr5-1352458512457850">5</xref></sup> Hence, we propose that EBV should be considered as playing a possible crucial role as a trigger in the pathogenesis of demyelinating processes.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare that there is no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512457850">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Owens</surname><given-names>GP</given-names></name>
<name><surname>Gilden</surname><given-names>D</given-names></name>
<name><surname>Burgoon</surname><given-names>MP</given-names></name>
<etal/>
</person-group>. <article-title>Viruses and multiple sclerosis</article-title>. <source>Neuroscientist</source> <year>2011</year>; <volume>14</volume>: <fpage>659</fpage>–<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512457850">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lucas</surname><given-names>RM</given-names></name>
<name><surname>Hughes</surname><given-names>AM</given-names></name>
<name><surname>Lay</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. <article-title>Epstein–Barr virus and multiple sclerosis</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2011</year>; <volume>82</volume>: <fpage>1142</fpage>–<lpage>1148</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512457850">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsartos</surname><given-names>JS</given-names></name>
<name><surname>Khan</surname><given-names>G</given-names></name>
<name><surname>Vossenkamper</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Association of innate immune activation with latent Epstein–Barr virus in active MS lesions</article-title>. <source>Neurology</source> <year>2012</year>; <volume>78</volume>: <fpage>15</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512457850">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sargsyan</surname><given-names>SA</given-names></name>
<name><surname>Shearer</surname><given-names>AJ</given-names></name>
<name><surname>Ritchie</surname><given-names>AM</given-names></name>
<etal/>
</person-group>. <article-title>Absence of Epstein–Barr virus in the brain and CSF of patients with multiple sclerosis</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume>: <fpage>1127</fpage>–<lpage>1135</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512457850">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Banwell</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>292</fpage>–<lpage>302</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>